A coalition of over 100 cancer groups is urging Congress to include the Clinical Treatment Act (HR-913) in an upcoming health care extenders package, scheduled to be considered this spring.
This story begins our occasional series looking back at the history of oncology since the signing of the National Cancer Act of 1971. The Cancer Letter was founded in 1973.
Explaining his decision to grant clemency to the financier Michael Milken, President Trump spoke thus:
When the Lung-MAP trial was launched in June 2014, the goal was simple: Make drug development faster and more collaborative—and do it for lung cancer, the leading cause of cancer death in the United States.This is a formidable challenge. Cancer trials were, and remain, notoriously time-consuming to launch, expensive to run, and difficult to enroll patients to. A deeper understanding of cancer biology and the genomics revolution in medicine have changed how we approach clinical research.When the Lung-MAP trial was launched in June 2014, the goal was simple: Make drug development faster and more collaborative—and do it for lung cancer, the leading cause of cancer death in the United States.
A program at Ohio State is trying to make use of cancer drugs that would otherwise go to waste.
The White House Feb. 10 released its FY21 budget proposal that, once again, includes drastic cuts to NIH and NCI.
Thomas Sellers, former director of Moffitt Cancer Center, has filed a lawsuit against his former institution, claiming defamation and tortious interference with a business relationship.
The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.
In what appears to be a significant reorganization, Gary Reedy, CEO of the American Cancer Society, announced to the staff of the Atlanta-based charity that he will be stepping away from its day-to-day operations.
If the mortality rate for lung cancer is starting to fall of a cliff in part because of treatment effect—contributing to more than a third of the 2.2% decline in overall cancer mortality from 2016 to 2017—is that signal showing up on the radar of NCI's Surveillance, Epidemiology, and End Results (SEER) Program?
